# OnCo record pfl-721 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/pfl-721/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "pfl-721" ;
  schema:name "PFL-721"@en ;
  schema:alternateName "STX-721"@en ;
  schema:description "PFL-721 is an experimental small molecule kinase inhibitor from Antares Therapeutics, in phase 1 trials for non-small cell lung cancer with EGFR or HER2 exon 20 insertion mutations."@en ;
  schema:url <https://onco.cc/drugs/pfl-721/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.biospace.com/press-releases/pierre-fabre-laboratories-strengthen-r-d-portfolio-and-announce-the-acquisition-of-the-worldwide-rights-for-pfl-721-and-pfl-241>, <https://www.biospace.com/press-releases/pierre-fabre-laboratories-strengthen-r-d-portfolio-and-announce-the-acquisition-of-the-worldwide-rights-for-pfl-721-and-pfl-241>, <https://antaresrx.com/>, <https://clinicaltrials.gov/api/v2/studies/NCT06043817>, <https://clinicaltrials.gov/search?intr=PFL-721> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Small molecule kinase inhibitor" ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:targets <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/her2/> ;
  onco:companies <https://onco.cc/companies/antares-therapeutics/>, <https://onco.cc/companies/pierre-fabre/> ;
  onco:trials <https://onco.cc/trials/nct06043817/> .